Delivering precision medicines for chronic multifactorial diseases
MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.
MultiOmic Health presents at LSX Investival 2024
Watch our CEO Robert Thong talk about how we are advancing precision medicine for metabolic-syndrome-related conditions at the LSX Investival Showcase in London.
MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease
MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.
Leveraging deep omics data to tackle a global health challenge with precision
We are excited to announce our feature in the most recent edition of Nature Portfolio’s Biopharma Dealmakers discussing the advances in AI-driven drug development.